Two months after it was approved for US marketing, Janssen-Cilag International's potential sales blockbuster, the interleukin-23 inhibitor MAb, Tremfya (guselkumab), has been recommended for approval in the EU for plaque psoriasis, a disease sector that is becoming increasingly competitive with the launch of new options to treat the disease and the emergence of biosimilar versions of long-established MAb-based therapies.
Around 14 million people in Europe have plaque psoriasis, and “the evidence shows this novel therapeutic offers significant and lasting...